A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19‐Year‐Old Female With Schizophrenia Authors: Wen‐mao Yang, Rui Li, Zhi‐quan Cui, Hua‐ning Wang, Qing‐rong Tan, Zheng‐wu Peng Published: 2026 ABSTRACT ABSTRACTA 19‐year‐old female with schizophrenia developed severe mixed tardive syndrome (choreoathetoid dyskinesia with prominent tardive dystonia) after antipsychotic treatment, which remained debilitating despite deutetrabenazine, benzodiazepines, baclofen, and amantadine. Over a 39‐day inpatient stay, switching the antipsychotic to clozapine and adding botulinum toxin injections plus the central muscle relaxant eperisone led to dramatic improvement, with the Abnormal Involuntary Movement Scale (AIMS) score falling from 32 to 8. Her psychosis also stabilized (PANSS 70 → 44). At 2‐month follow‐up, the regimen was simplified with sustained benefit. This case illustrates that a multimodal strategy—combining a low‐D2‐affinity antipsychotic, a VMAT2 inhibitor, and targeted muscle relaxation—was associated with marked improvement in this patient with refractory mixed tardive syndrome. However, given the near‐simultaneous implementation of multiple interventions, the relative contribution of each component cannot be definitively determined, and controlled studies are needed to establish the efficacy of this approach. Introduction Tardive dyskinesia (TD) is a potentially persistent movement disorder that affects approximately 32% of patients with schizophrenia and 21% of those with other severe mental disorders following exposure to antipsychotic medications [1]. Beyond antipsychotics, TD‐like syndromes have also been associated with other centrally acting drugs, such as lithium and certain anticonvulsants [2]. Although second‐generation antipsychotics (SGAs) carry a significantly lower risk of TD compared to first‐generation antipsychotics (FGAs), the condition remains clinically relevant. For instance, among patients treated exclusively with SGAs, the prevalence of TD is estimated at 7.2%, with an annualized incidence rate of 2.6% in previously TD‐free individuals [3]. A commonly proposed strategy in clinical practice for managing TD is to reduce or temporarily discontinue the offending antipsychotic agent [4, 5]. However, evidence supporting this approach remains inconclusive. In many cases, TD persists for years or even decades after antipsychotic withdrawal [6]. Moreover, dose reduction may paradoxically worsen both dyskinetic symptoms and underlying psychiatric conditions [7, 8]. Several pharmacological interventions are available for TD. Vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine and deutetrabenazine, have been approved by the U.S. Food and Drug Administration (FDA) for TD management [9]. For tardive dystonia, treatment options include benzodiazepines, anticholinergic agents, baclofen, and botulinum toxin injections. Nevertheless, a substantial proportion of patients—10% to 30% with TD and up to 50% with tardive dystonia—do not respond adequately to existing therapies [7, 10]. Given these limitations, there is a clear and pressing need to develop novel, effective treatment strategies for TD. Furthermore, the potential of combination drug therapies remains underexplored, and their efficacy in mitigating tardive syndromes has yet to be systematically evaluated. Here we report the case of a female adolescent with a severe mixed tardive syndrome who showed substantial clinical improvement after a 39‐day inpatient course of combination pharmacotherapy, highlighting the diagnostic challenges and the potential of a multimodal treatment approach. Case Presentation Patient Information A 19‐year‐old, unmarried, unemployed female from Fuping County, China, was admitted to our Psychosomatic Department on July 13, 2025. Chief Complaints Emotional instability and suspiciousness for 4 years, accompanied by involuntary movements and motor impairment for over 3 years. History of Present Illness 2021: The patient initially presented with emotional instability, irritability, and aggressive behavior. She was diagnosed with “Adolescent Emotional Disorder” and briefly treated with Olanzapine. By September, she developed paranoid delusions (believing classmates were talking about and mocking her) and was diagnosed with “Childhood‐onset Behavioral and Emotional Disorder” and “Paranoid State”. Treatment with Aripiprazole (up to 40 mg/day) and Benztropine was initiated but poorly tolerated and irregularly adhered to. 2022: Her psychotic symptoms worsened, with ideas of reference and persecution involving teachers and classmates. She exhibited significant emotional lability, had physical conflicts, and displayed disinhibited behavior online. She eventually dropped out of school. 2023: Symptoms escalated with aggression, property destruction, disorganized behavior (walking miles at night), self‐neglect, and obvious social withdrawal. Auditory hallucinations (muttering and laughing to herself) and persistent delusions were noted. In November, she was hospitalized and treated with Paliperidone (9 mg), which was effective for her psychosis. 2024 (Critical Turning Point): In October, she developed muscle pain, followed by severe involuntary movements including choreoathetotic movements of the upper limbs, head, and neck; dysarthria (“thick tongue” speech); finger contortions; and torticollis. The movements were so severe they impaired walking and breathing. Paliperidone was discontinued and switched to Olanzapine, with only transient improvement. She was subsequently hospitalized multiple times at different centers. Her diagnosis was confirmed as “Tardive Dyskinesia”. Treatments trialed during this period included: Bunanselin, Tiapride, Lorazepam/Clonazepam, Baclofen, Deutetrabenazine (which caused nausea), Vitamin E and MECT. While her mood stabilized, her motor symptoms remained severe and fluctuating, characterized by orofacial dyskinesia, retrocollis (neck extension), and dystonic posturing of the right arm. 2025: In May, a neurologist at Peking Union Medical College Hospital recommended a trial of Amantadine (200 mg/day), which was discontinued by the family after 1 week due to perceived lack of efficacy. Botulinum Toxin therapy was suggested. She was admitted to our department for further management. Past Medical, Personal, and Family History The patient was previously healthy with no chronic diseases. Her personal history revealed a stressful early childhood in a boarding kindergarten where she reported mistreatment. She was described as competitive and somewhat solitary in primary school but performed well academically and socially in middle school before her psychiatric breakdown during high school. There was no family history of psychiatric, neurological, or genetic disorders. Diagnostic and Admission Assessment On admission, her primary diagnoses were schizophrenia and refractory Tardive Dyskinesia with features of tardive dystonia. A previous brain MRI (March 2025) showed ventricular enlargement. The total Positive and Negative Syndrome Scale (PANSS) score was 70, and the Abnormal Involuntary Movement Scale (AIMS) score was 32. The AIMS severity score breakdown was: 4 (facial and oral), 4 (extremity), 4 (trunk), and 4 (global severity), indicating severe dyskinesia across all domains. After obtaining informed consent, the patient was filmed during an episode of severe motor exacerbation (Figure 1; Video 1). Patient exhibiting severe motor impairment upon admission. Severe mixed tardive syndrome at admission. Video content can be viewed at https://onlinelibrary.wiley.com/doi/10.1002/ccr3.73466. Therapeutic Intervention During her inpatient stay at our department, a comprehensive treatment plan was implemented: First, Bunanselin and Tiapride were discontinued and replaced with Clozapine which was titrated to a therapeutic dose for her psychotic symptoms. The initial dose was 75 mg/day. After 1 week, it was increased to 125 mg/day and maintained until discharge. Second, two sessions of botulinum toxin type A (onabotulinumtoxinA, Botox; 100 U/vial reconstituted with 2.5 mL of 0.9% preservative‐free saline, yielding a concentration of 4 U/0.1 mL) were administered under electromyographic guidance on August 1 and August 13, 2025. Target muscles were selected based on detailed clinical examination identifying the most painful and functionally disabling dystonic muscles in the neck and upper back. Electromyography guidance was employed to confirm needle placement within dystonically active motor units. All injections were performed by a neurologist with subspecialty expertise in movement disorders (Q.R.T.) using a 27‐gauge, 0.5‐in. needle. The injected muscles and doses were as follows: for each session, the splenius capitis received 50 U per side (100 U total) to address retrocollis; the trapezius (upper fibers) received 30 U per side (60 U total) to address shoulder elevation and neck extension; and the levator scapulae received 20 U per side (40 U total) to address scapular retraction. The total dose per session was 200 U, with a cumulative inpatient dose of 400 U over the two sessions. Third, Eperisone (17.5 mg/day), a central muscle relaxant, was added orally to alleviate generalized muscle stiffness and pain. Finally, the existing medications, Deutetrabenazine (24 mg/day), Baclofen (15 mg/day), Clonazepam (6 mg/day), and Vitamin E (600 mg/day), were continued as part of the foundational TD management. Follow‐Up and Outcomes After initiation of the new regimen for 39 days, the patient showed marked clinical improvement. The frequency and severity of her involuntary movements, particularly the painful retrocollis and arm posturing, significantly reduced. Her dysarthria improved, allowing for clearer speech. Subjectively, she reported less pain and distress, leading to improved overall functioning and participation in daily activities. Her PANSS score decreased to 44 (Positive subscale: 9; Negative subscale: 11; General Psychopathology subscale: 24), and her AIMS score improved to 8. The follow‐up AIMS severity score breakdown was: 1 (facial and oral), 1 (extremity), 1 (trunk), and 1 (global severity). Videos of the patient dancing at home are available (Figure 2; Video 2). Patient dancing at home after 39 days of a multimodal treatment regimen, demonstrating a marked reduction in involuntary movements. Clinical improvement at discharge. Video content can be viewed at https://onlinelibrary.wiley.com/doi/10.1002/ccr3.73466. After discharge, the patient continued the treatment plan. Two months later, due to significant and sustained improvement, we discontinued Eperisone and adjusted dosages to: Clozapine (100 mg/day), Deutetrabenazine (12 mg/day), Baclofen (15 mg/day), Clonazepam (6 mg/day), and Vitamin E (300 mg/day). In the recent follow‐up (November 6th), the patient had a normal gait and stable emotions (Figure 3; Video 3). Together, the initiation of each treatment and the corresponding changes in symptoms were illustrated in Figure 4 and Table 1. Patient at the 2‐month follow‐up visit on November 6, showing a normal gait with no residual involuntary movements and stable mood. Two‐month follow‐up visit. Video content can be viewed at https://onlinelibrary.wiley.com/doi/10.1002/ccr3.73466. Clinical timeline and treatment interventions. Upper panel: Trajectory of psychiatric and movement disorder severity. Lower panel: Timeline of pharmacological interventions. AIMS, abnormal involuntary movement scale; BoNT, Botulinum Neurotoxin; PANSS, Positive and Negative Syndrome Scale; TD, Tardive Dyskinesia. TABLE 1Comprehensive treatment timeline and clinical course.DateEvent/InterventionMedicationsAIMS (PANSS) scoreClinical notes2021Initial psychiatric symptoms; olanzapine trialOlanzapine—Diagnosed with emotional disorderSep 2021Paranoid delusions developAripiprazole 40 mg + Benztropine—Poor tolerance, irregular adherence2022Psychosis worsens; drops out of school——Ideas of reference, aggression, disinhibitionNov 2023Hospitalized; paliperidone initiatedPaliperidone 9 mg—Effective for psychosisOct 2024Onset of tardive syndromePaliperidone → Olanzapine—Muscle pain, choreoathetosis, dystonia; multiple hospitalizationsLate 2024Multiple TD treatments trialedBunanselin, tiapride, lorazepam/clonazepam, baclofen, deutetrabenazine, vitamin E, MECT—Mood stabilized; motor symptoms severe and fluctuatingMay 2025Amantadine trial (discontinued)Amantadine 200 mg (1 week)—Discontinued due to perceived lack of efficacy; BoNT suggestedJul 13, 2025Admission to our departmentDeutetrabenazine 24 mg, baclofen 15 mg, clonazepam 6 mg, vitamin E 600 mg32 (PANSS: 70)Severe mixed tardive syndrome; Bunanselin and tiapride discontinuedJul 13–20, 2025Clozapine titrationClozapine 75 mg → 125 mg—Gradual titration for psychotic symptomsAug 1, 2025First BoNT injectionBoNT (neck, upper back) + eperisone 17.5 mg added—EMG‐guided; targeting retrocollis and arm dystoniaAug 13, 2025Second BoNT injectionBoNT (same targets)—Identical protocol to first sessionAug 21, 2025Discharge (39 days)Clozapine 125 mg, deutetrabenazine 24 mg, baclofen 15 mg, clonazepam 6 mg, vitamin E 600 mg, eperisone 17.5 mg8 (PANSS: 44)Marked improvement in movements, speech, pain; daily functioning restoredSep–Oct 2025Outpatient follow‐upSame regimen—Sustained improvement maintainedOct 2025Regimen simplificationEperisone discontinued; clozapine 100 mg, deutetrabenazine 12 mg, baclofen 15 mg, clonazepam 6 mg, vitamin E 300 mg—No recurrence after eperisone discontinuationNov 6, 2025Two‐month follow‐upSimplified regimen continued—Normal gait, stable emotions, fluent speech; no residual movements Comprehensive treatment timeline and clinical course. Discussion The diagnosis and management of TD present a complex clinical challenge. This case is particularly instructive because the patient exhibited a mixed tardive syndrome, combining classic choreoathetoid TD (as seen in the orofacial and limb movements) with prominent, severe tardive dystonia (manifesting as retrocollis, torticollis, and dystonic arm posturing). Clinically, TD is characterized by involuntary movements that most commonly affect the orofacial region (e.g., grimacing, lip puckering, tongue protrusion) but can also involve the trunk and limbs [11, 12]. These movements often progress from being mild and unnoticed by the patient to severely debilitating, potentially leading to physical complications, impaired speech and swallowing, and even respiratory difficulties [13]. The management of TD remains difficult, with limited treatment options and the potential for symptoms to become irreversible, underscoring the serious nature of this drug‐induced movement disorder [14]. The pathophysiology of TD is primarily linked to sustained blockade of dopamine D2 receptors. The prevailing theory of dopaminergic supersensitivity posits that prolonged receptor antagonism leads to compensatory upregulation, rendering certain neural pathways hypersensitive to dopamine and resulting in characteristic hyperkinetic movements [15]. A complementary theory emphasizes the role of oxidative stress, suggesting that neuronal injury and motor circuit dysfunction arise from reactive oxygen species accumulated during long‐term antipsychotic therapy, particularly in individuals with compromised antioxidant defenses [16]. Furthermore, GABAergic dysfunction is implicated in TD, as reduced gamma‐aminobutyric acid (GABA)‐mediated inhibitory control within the basal ganglia may disrupt the balance between excitation and inhibition, contributing to motor symptoms [17, 18]. Given these mechanistic complexities, the pharmacological management of TD requires a multifaceted approach. A recent systematic review and network meta‐analysis indicates that, based on higher‐quality evidence, valbenazine and deutetrabenazine represent the sole evidence‐based first‐line pharmacotherapies, while vitamin E may be considered a second‐line option [19]. In the present case, the patient's initial regimen of deutetrabenazine, clonazepam, baclofen, and vitamin E, while based on sound pathophysiological reasoning [20, 21], provided only partial and transient benefits. While her mood stabilized, her severe dystonic and choreiform movements remained debilitating after 3 months. This suggests that while this combination can be a useful foundation, it may be insufficient for severe, refractory cases, particularly those with a prominent tardive dystonia component. It is important to emphasize that the design of this case report—a single‐patient, uncontrolled, observational study with multiple near‐simultaneous interventions—does not permit causal inference regarding the superiority of combination therapy over any individual intervention. The observed improvement may reflect the effect of one dominant intervention, a synergistic interaction, the natural history of the disorder, or a placebo effect. For further management, the treatment strategy was modified during inpatient care. First, Bunanselin and tiapride were replaced with clozapine. Clozapine is a second‐generation antipsychotic with low affinity for D2 dopamine receptors and high antagonism at 5‐HT2A receptors, a pharmacological profile that theoretically reduces dopaminergic supersensitivity and provides effective psychiatric control with minimal extrapyramidal burden [22]. The switch to clozapine in this case may have contributed to improvement, consistent with systematic reviews and retrospective studies reporting symptomatic benefit in a substantial proportion of patients with tardive syndromes [23, 24, 25]. However, several caveats warrant emphasis. Current guidelines, including the APA Practice Guideline for schizophrenia, do not recommend clozapine as a first‐line treatment for tardive dyskinesia or dystonia [8]. Moreover, clozapine carries significant risks—agranulocytosis, metabolic syndrome, myocarditis, and seizures—that mandate strict hematological monitoring and must be carefully weighed against any potential, unproven benefit [26]. In the present case, the benefit may also reflect the removal of a high‐D2‐affinity agent (paliperidone) rather than a specific therapeutic effect of clozapine itself. Given the predominantly observational evidence and absence of RCTs, this interpretation remains speculative, and clozapine use for established tardive syndrome should be considered only on an individualized basis, with rigorous monitoring, and ideally within a research context. Second, BoNT and eperisone were introduced to address the focal dystonic and hyperkinetic components. BoNT provides potent, targeted chemodenervation by inhibiting acetylcholine release at the neuromuscular junction, while eperisone, a central muscle relaxant, reduces muscle tone by inhibiting mono‐ and polysynaptic reflexes at the spinal level, helping to alleviate pain and stiffness associated with muscle tension [27]. The rationale for this combination lies in their complementary mechanisms: BoNT provides focal, potent chemodenervation, while eperisone offers a more generalized reduction in muscle tone and spasticity. Of note, BoNT was administered only during the two inpatient sessions and was not continued after discharge. Despite this, the patient remained clinically stable at the 2‐month follow‐up. We do not attribute this sustained improvement solely to BoNT; rather, we propose that the initial injections provided acute symptomatic relief, particularly for the painful retrocollis and dystonic arm posturing, which may have facilitated functional rehabilitation and enabled the other pharmacological interventions to take effect in a less symptomatically burdened state. Alternatively, the improvement could reflect the natural course of tardive syndrome after withdrawal of the offending antipsychotic, the ongoing effects of clozapine and deutetrabenazine, or a combination of these factors. Although a few case reports have described prolonged benefits of BoNT in tardive dystonia [28, 29], such evidence remains anecdotal and not generalizable. Furthermore, the sustained improvement allowed for a subsequent simplification of the regimen, with the successful discontinuation of eperisone and dose reductions of other medications, suggesting that the core benefits were driven by the ongoing pharmacological effects of clozapine and/or deutetrabenazine, or the natural course of the disorder following antipsychotic switch. This case is consistent with a previous report of clozapine combined with tetrabenazine and BoNT for aripiprazole‐induced TD [30] and extends the observation to a mixed tardive syndrome in an adolescent. The novelty of our report lies not in the individual use of BoNT, but in the description of a successful, multi‐layered, “add‐on” strategy for a severe, debilitating mixed tardive syndrome that was refractory to standard, first‐line therapies. Conclusion This case report demonstrates that a multimodal combination of Clozapine, Deutetrabenazine, Botulinum Toxin, and Eperisone can be a highly effective strategy for managing severe, refractory mixed tardive syndrome. The case highlights the importance of accurately identifying and addressing overlapping tardive phenomenologies. However, it is important to emphasize that the near‐simultaneous implementation of multiple interventions precludes definitive attribution of the observed improvement to any single agent or to the combination per se. The antipsychotic switch to Clozapine may have been the dominant driver of improvement, with other interventions providing adjunctive symptomatic relief. Controlled trials are needed to evaluate the efficacy, safety, and relative contributions of each component in this therapeutic approach for similarly challenging cases where standard therapies have failed. Limitations This study has several limitations. First, as a single‐case report, its findings cannot be generalized. Second, the exact contribution of each therapeutic component cannot be definitively determined, and the long‐term safety and tolerability of this polypharmacy approach remain unestablished. Future research involving larger cohorts and extended follow‐up is necessary to evaluate the efficacy, safety, and sustainability of this treatment strategy. Author Contributions Wen‐mao Yang: investigation, writing – original draft, data curation. Rui Li: investigation, data curation. Zhi‐quan Cui: data curation, investigation. Hua‐ning Wang: methodology, supervision. Qing‐rong Tan: conceptualization, supervision. Zheng‐wu Peng: validation, writing – review and editing, resources. Funding The authors have nothing to report. Ethics Statement Ethics approval and consent were not sought nor obtained due to it not being needed in this case report. Consent Written informed consent for publication has been obtained from the patient in this study. Conflicts of Interest The authors declare no conflicts of interest.